Loading...
Loading...
ATHX| Name | Value |
|---|---|
| Revenues | 2.3M |
| Cost of Revenue | 0.0M |
| Gross Profit | 2.3M |
| Operating Expense | 26.6M |
| Operating I/L | -24.3M |
| Other Income/Expense | 0.6M |
| Interest Income | 0.0M |
| Pretax | -23.6M |
| Income Tax Expense | -0.6M |
| Net Income/Loss | -23.0M |
Athersys, Inc. is a biotechnology company specializing in regenerative medicine. Its primary focus is on the development of MultiStem cell therapy, an allogeneic stem cell product currently in Phase III clinical study for treating neurological damage from ischemic stroke and acute respiratory distress syndrome, among other indications. The company also collaborates with Healios K.K. to develop and commercialize MultiStem cell therapy for various medical conditions. Athersys generates revenue through the development and potential commercialization of its regenerative medicine products, aiming to address unmet medical needs in neurological conditions, cardiovascular diseases, and other areas.
